ArticleBMC cardiovascular disorders2025
Circulating MicroRNA-1 for the early prediction of unstable angina and the value of second coronary angiography in type 2 diabetes patients with chest pain and no ST-T changes on electrocardiograms.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic Accuracy of Circulating MicroRNAs for Coronary Artery Disease: An Updated Systematic Review and Meta-analysis.Journal of cardiovascular translational research · 2026Pooled it
- Clinical significance of lncRNA GAS5 in deep vein thrombosis and its mechanism of action on vascular endothelial damage.BMC cardiovascular disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTo investigate the early diagnostic value of circulating microRNA-1 for unstable angina (UA) in type 2 diabetes patients presenting with chest pain as the main symptom and without ST-T changes on electrocardiograms and to assess the predictive value of microRNA-1 for the need for a second coronary angiography (CAG) in these UA patients.
methodsAll hospitalized patients with chest pain undergoing first-time CAG demonstrated no ST-T changes on initial and pre-CAG electrocardiograms and normal initial high-sensitivity cardiac troponin I levels. Plasma microRNA-1 levels were measured via quantitative reverse transcription polymerase chain reaction within 3 h of chest pain onset. UA patients were followed up for 5 years through phone calls and outpatient visits. The endpoints included second CAG and all-cause mortality.
resultsA total of 127 patients were enrolled, with 62 in the UA group and 65 in the non-UA group. MicroRNA-1, low-density lipoprotein cholesterol, and diabetes duration were significantly greater in the UA group than in the non-UA group. The area under the receiver operating characteristic curve for microRNA-1 in diagnosing UA was 0.811. Binary logistic regression analysis indicated that microRNA-1 and low-density lipoprotein cholesterol were predictive factors for UA. No UA patients were lost to follow-up or died during the follow-up period. Patients who underwent a second CAG had significantly higher microRNA-1 levels than those who did not. Binary logistic regression revealed that microRNA-1 and hemoglobin a1c were predictive factors for second CAG in UA patients during follow-up. Cox regression analysis revealed that microRNA-1 was an independent risk factor for a second CAG during follow-up in UA patients. Using the Youden index, the optimal cut-off value of microRNA-1 (2
conclusionsFor type 2 diabetes patients with acute chest pain, no ST-T changes on electrocardiograms, and negative high-sensitivity cardiac troponin I, microRNA-1 may offer early diagnostic value for UA and could serve as an independent risk factor for the need for a second CAG within 5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.